Cellectis S.A. (NASDAQ:CLLS) Receives Average Recommendation of “Moderate Buy” from Brokerages

Cellectis S.A. (NASDAQ:CLLS) has earned a consensus rating of “Moderate Buy” from the six brokerages that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, four have given a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among brokers that have covered the stock in the last year is $7.00.

A number of equities research analysts have recently commented on CLLS shares. Barclays began coverage on Cellectis in a research note on Thursday, May 28th. They issued an “overweight” rating and a $9.00 target price on the stock. Jefferies Financial Group started coverage on shares of Cellectis in a report on Tuesday, February 17th. They issued a “buy” rating and a $7.00 price objective for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Cellectis in a report on Monday, April 20th. Finally, Citizens Jmp reissued a “market outperform” rating and issued a $8.00 target price on shares of Cellectis in a report on Tuesday, April 14th.

Institutional Trading of Cellectis

A number of institutional investors and hedge funds have recently modified their holdings of CLLS. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in Cellectis by 228.4% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,722,664 shares of the biotechnology company’s stock valued at $5,856,000 after acquiring an additional 3,284,409 shares during the period. Acadian Asset Management LLC lifted its stake in Cellectis by 132.9% during the 1st quarter. Acadian Asset Management LLC now owns 46,377 shares of the biotechnology company’s stock valued at $55,000 after acquiring an additional 26,461 shares during the period. Delaney Dennis R bought a new position in Cellectis during the 3rd quarter valued at about $68,000. B Group Inc. lifted its stake in Cellectis by 0.8% during the 3rd quarter. B Group Inc. now owns 3,281,501 shares of the biotechnology company’s stock valued at $9,352,000 after acquiring an additional 25,000 shares during the period. Finally, Virtu Financial LLC bought a new position in Cellectis during the 3rd quarter valued at about $72,000. Institutional investors own 63.90% of the company’s stock.

Cellectis Stock Down 8.6%

CLLS stock opened at $3.09 on Thursday. Cellectis has a twelve month low of $1.33 and a twelve month high of $5.48. The company has a quick ratio of 1.52, a current ratio of 1.52 and a debt-to-equity ratio of 1.13. The firm has a market cap of $310.05 million, a PE ratio of -4.61 and a beta of 2.86. The business has a 50 day moving average of $3.70 and a 200 day moving average of $4.03.

Cellectis (NASDAQ:CLLS) last released its earnings results on Monday, May 11th. The biotechnology company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.08. Cellectis had a negative return on equity of 80.66% and a negative net margin of 89.51%.The firm had revenue of $7.55 million for the quarter, compared to analysts’ expectations of $11.04 million.

Cellectis Company Profile

Cellectis is a clinical‐stage biopharmaceutical company specializing in the development of gene‐edited cell therapies for oncology. Founded in 1999 and headquartered in Paris, France, the company also maintains operations in New York City and Raleigh, North Carolina. Cellectis applies its proprietary TALEN genome editing platform to engineer allogeneic chimeric antigen receptor T‐cell (CAR‐T) candidates designed to target blood cancers and solid tumors.

The company’s core business activities encompass the discovery, development and manufacturing of off‐the‐shelf immunotherapies.